TrialHematological oncology2025

Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.

Christian Rausch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.